J&J (JNJ) Seeks Expanded Use of HIV Drug in US and Europe

Johnson & Johnson (JNJ) announced that it has submitted a supplemental new drug application (sNDA) seeking expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States.Prezcobix is a two-drug fixed-dose combination tablet for treating HIV-1 infection in treatment-naïve and treatment-experienced adults and adolescent patients weighing at least 40 kg. It combines darunavir, J&J’s HIV-1 protease inhibitor, and cobicistat, Gilead Sciences’ (GILD) CYP3A inhibitor. J&J markets darunavir as ...